Dear European Organization for Professionals and Patients with ALS, Thank you for your request to receive updates about QALSODY® (tofersen). We are writing with the news that the Committee for Medicinal… More >>

The Phase 2 HIMALAYA clinical trial evaluating SAR443820/DNL788 in participants with amyotrophic lateral sclerosis (ALS) did not meet the primary endpoint of change in ALS Functional Rating ScaleRevised (ALSFRS-R). The… More >>

Grant and Award Announcement UNIVERSITAIR MEDISCH CENTRUM GRONINGEN IMAGE: PROFESSOR ROBERT SCHOEVERS AT A THERAPEUTIC SESSION CREDIT: UMCG The randomised controlled trial (RCT) PsyPal, coordinated by the University Medical Centre… More >>

AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency A decision from the european medicines agency is expected… More >>

Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, will present clinical… More >>

Ferrer reports that Phase III ADORE clinical trial of oral edaravone formulation (FAB122) in amyotrophic lateral sclerosis (ALS) patients did not meet primary or key secondary endpoints. The ADORE clinical… More >>

Top-Line Results from 6-month double-blind Phase 2b PARADIGM trial with NeuroSense’s lead drug candidate for ALS, PrimeC, include: NeuroSense Therapeutics, a company developing treatments for severe neurodegenerative diseases, reported that… More >>

Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process CAMBRIDGE, Mass.– Amylyx Phammaceuticals. Inc.… More >>